reversan

N/A

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug Namereversan
Drug Alias NameMRP1 inhibitors (Cleveland BioLabs)multidrug resistance-associated protein 1 inhibitors (Cleveland BioLabs)reversan (Statera Biopharma/Children's Cancer Institute Australia for Medical Research)MRP1 inhibitors (Cleveland BioLabs/Children's Cancer Institute Australia for Medical Research)CBLC-4H10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP-glycoprotein 1 inhibitors
TargetsP-glycoprotein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesChildrens Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesStatera Biopharma IncChildrens Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A